Papers/PMID:41087029
Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.
Clinical and molecular hepatology2026The record
2 findings drawn from this paper, on 1 compound across 2 endpoints.
What it reported
How to read these marksWhat moved
2 findings
berberine — decreases alanine aminotransferase
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Finding“However, oral administration of BBR not only reversed hepatocyte necrosis, but also decreased the elevated levels of TBA, ALP, TBIL, DBIL, ALT, and AST ( Supplementary Fig. 1A, 1B).”
Quoted verbatim from Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.. - Study
- animal · not in humans
- Duration
- 7 days
- Population
- C57BL/6J mice with bile duct ligation-induced cholestatic liver injury; serum ALT by automated biochemical analyser
Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.2026PMID:41087029
berberine — decreases aspartate aminotransferase
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Finding“However, oral administration of BBR not only reversed hepatocyte necrosis, but also decreased the elevated levels of TBA, ALP, TBIL, DBIL, ALT, and AST ( Supplementary Fig. 1A, 1B).”
Quoted verbatim from Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.. - Study
- animal · not in humans
- Duration
- 7 days
- Population
- C57BL/6J mice with bile duct ligation-induced cholestatic liver injury; serum AST by automated biochemical analyser
Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.2026PMID:41087029